Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was formed to produce improved, more potent shots that are simpler to manufacture.

This week his SpaceX reportedly filed confidentially for a $75 billion initial public offering that could value it at $1.75T.